Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal
- PMID: 38006470
- DOI: 10.1007/s10741-023-10370-x
Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal
Erratum in
-
Correction to: Clinical staging of Anderson‑Fabry cardiomyopathy: an operative proposal.Heart Fail Rev. 2024 Mar;29(2):571. doi: 10.1007/s10741-023-10379-2. Heart Fail Rev. 2024. PMID: 38294670 No abstract available.
Abstract
As a slowly progressive form of hypertrophic cardiomyopathy (HCM), Anderson-Fabry disease (FD) resembles the phenotype of the most common sarcomeric forms, although significant differences in presentation and long-term progression may help determine the correct diagnosis. A variety of electrocardiographic and imaging features of FD cardiomyopathy have been described at different times in the course of the disease, and considerable discrepancies remain regarding the assessment of disease severity by individual physicians. Therefore, we here propose a practical staging of FD cardiomyopathy, in hopes it may represent the standard for cardiac evaluation and facilitate communication between specialized FD centres and primary care physicians. We identified 4 main stages of FD cardiomyopathy of increasing severity, based on available evidence from clinical and imaging studies: non-hypertrophic, hypertrophic - pre-fibrotic, hypertrophic - fibrotic, and overt dysfunction. Each stage is described and discussed in detail, following the principle that speaking a common language is critical when managing such complex patients in a multi-disciplinary and sometimes multi-centre setting.
Keywords: Anderson-Fabry cardiomyopathy; Clinical management; Myocardial disease progression; Staging.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Weidemann F, Breunig F, Beer M, Sandstede J, Störk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 26:1221–1227. https://doi.org/10.1093/eurheartj/ehi143 - DOI - PubMed
-
- Pieroni M, Moon JC, Arbustini E, Barriales-Villa R, Camporeale A, Vujkovac AC, Elliott PM, Hagege A, Kuusisto J, Linhart A, Nordbeck P, Olivotto I, Pietilä-Effati P, Namdar M (2021) Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol 77:922–936. https://doi.org/10.1016/j.jacc.2020.12.024 - DOI - PubMed
-
- Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M, Sunder-Plassmann G, Investigators FOS (2009) Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry outcome survey. J Med Genet 46:548–552. https://doi.org/10.1136/jmg.2008.065904 - DOI - PubMed
-
- Orsborne C, Bradley J, Bonnett LJ, Pleva LA, Naish JH, Clark DG, Abidin N, Woolfson P, Nucifora G, Schmitt M, Jovanovic A, Miller CA, Reid AB (2022) Validated model for prediction of adverse cardiac outcome in patients with Fabry disease. J Am Coll Cardiol 80:982–994. https://doi.org/10.1016/j.jacc.2022.06.022 - DOI - PubMed
-
- Nordin S, Kozor R, Medina-Menacho K, Abdel-Gadir A, Baig S, Sado DM, Lobascio I, Murphy E, Lachmann RH, Mehta A, Edwards NC, Ramaswami U, Steeds RP, Hughes D, Moon JC (2019) Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging 12:1673–1683. https://doi.org/10.1016/j.jcmg.2018.03.020 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
